DaVita said net cash provided by operating activities for the nine months ended September 30, 2024 decreased from the prior-year period. The company cited decreased cash collections from the CHC Outage and higher cash taxes paid as the factors. It said improved operating results and an increase in other working capital items partially offset the decline.

10-QQuarterly reportFiled Oct 29, 2024Period of report Sep 30, 2024Summary published (UTC) Oct 23, 2026

Key points

AI summary

DaVita said net cash provided by operating activities for the nine months ended September 30, 2024 decreased from the prior-year period. The company cited decreased cash collections from the CHC Outage and higher cash taxes paid as the factors. It said improved operating results and an increase in other working capital items partially offset the decline.
DaVita said it extended the maturity of a portion of its Term Loan B-1 (about $1,640 million) from August 2026 to May 2031 during 2024, and raised $1,100 million under an Incremental Term Loan A-1 and $1,000 million of 6.875% senior notes. Over the same period, it prepaid about $2,590 million of Term Loan B-1 and repurchased 7,507,842 shares. The company's 9-month period is covered in this item.
The company said its U.S. dialysis center closure charges were approximately $18.3 million (approximately $15.3 million in Q2) in Q3 2024. Cumulative charges for the 9 months were approximately $48.2 million, compared with approximately $67.3 million a year earlier, and it expects closure rates to remain at elevated levels over the remainder of 2024.
DaVita said U.S. dialysis patient care costs per treatment rose in Q3 2024 from Q2. The company cited higher compensation expenses, including increased wage rates and payroll taxes, as the main driver. It said higher average patient service revenue per treatment and treatment volume affected operating income.

Key figures

Quarter ended September 30, 2024

Revenue: $3.3B
Operating income: $535M
Net income: $215M
EPS: $2.50

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

CHC Cybersecurity Outage and Lower Operating Cash Flow

DaVita said net cash provided by operating activities for the nine months ended September 30, 2024 decreased from the prior-year period. The company cited decreased cash collections from the CHC Outage and higher cash taxes paid as the factors. It said improved operating results and an increase in other working capital items partially offset the decline.

Source · Based on the MD&A text of the filing

9-Month Debt Transactions and Share Repurchases

DaVita said it extended the maturity of a portion of its Term Loan B-1 (about $1,640 million) from August 2026 to May 2031 during 2024, and raised $1,100 million under an Incremental Term Loan A-1 and $1,000 million of 6.875% senior notes. Over the same period, it prepaid about $2,590 million of Term Loan B-1 and repurchased 7,507,842 shares. The company's 9-month period is covered in this item.

Source · Based on the MD&A text of the filing

U.S. Dialysis Center Closure Costs

The company said its U.S. dialysis center closure charges were approximately $18.3 million (approximately $15.3 million in Q2) in Q3 2024. Cumulative charges for the 9 months were approximately $48.2 million, compared with approximately $67.3 million a year earlier, and it expects closure rates to remain at elevated levels over the remainder of 2024.

Source · Based on the MD&A text of the filing

U.S. Dialysis Patient Care Costs and Operating Income Drivers

DaVita said U.S. dialysis patient care costs per treatment rose in Q3 2024 from Q2. The company cited higher compensation expenses, including increased wage rates and payroll taxes, as the main driver. It said higher average patient service revenue per treatment and treatment volume affected operating income.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.